SiBone (NASDAQ:SIBN – Get Free Report) Director Jeffrey Dunn sold 3,575 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $15.25, for a total transaction of $54,518.75. Following the sale, the director directly owned 16,057 shares in the company, valued at $244,869.25. This represents a 18.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
SiBone Price Performance
NASDAQ SIBN traded down $0.15 during trading hours on Monday, reaching $14.97. 350,701 shares of the company’s stock were exchanged, compared to its average volume of 650,203. The firm has a fifty day moving average of $13.68 and a 200-day moving average of $15.94. SiBone has a one year low of $11.48 and a one year high of $21.89. The stock has a market cap of $663.90 million, a PE ratio of -38.38 and a beta of 0.70. The company has a current ratio of 9.99, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20.
SiBone (NASDAQ:SIBN – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The company had revenue of $52.59 million for the quarter, compared to analyst estimates of $51.16 million. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%. On average, equities research analysts predict that SiBone will post -0.44 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of equities research analysts have commented on SIBN shares. Truist Financial reissued a “buy” rating and set a $18.00 price objective (down from $20.00) on shares of SiBone in a report on Tuesday, May 12th. Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, TD Cowen reduced their target price on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SiBone has an average rating of “Moderate Buy” and an average price target of $23.00.
Get Our Latest Stock Analysis on SiBone
SiBone Company Profile
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
Featured Stories
- Five stocks we like better than SiBone
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
